Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors

Studies on HIV dynamics in AIDS research are very important in understanding the pathogenesis of HIV-1 infection and also in assessing the effectiveness of antiretroviral (ARV) treatment. Viral dynamic models can be formulated through a system of nonlinear ordinary differential equations (ODE), but there has been only limited development of statistical methodologies for inference. This article, motivated by an AIDS clinical study, discusses a hierarchical Bayesian nonlinear mixed-effects modeling approach to dynamic ODE models without a closed-form solution. In this model, we fully integrate viral load, medication adherence, drug resistance, pharmacokinetics, baseline covariates and time-dependent drug efficacy into the data analysis for characterizing long-term virologic responses. Our method is implemented by a data set from an AIDS clinical study. The results suggest that modeling HIV dynamics and virologic responses with consideration of time-varying clinical factors as well as baseline characteristics may be important for HIV/AIDS studies in providing quantitative guidance to better understand the virologic responses to ARV treatment and to help the evaluation of clinical trial design in response to existing therapies.

[1]  Marie Davidian,et al.  A Two-Step Approach to Measurement Error in Time-Dependent Covariates in Nonlinear Mixed-Effects Models, with Application to IGF-I Pharmacokinetics , 1997 .

[2]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[3]  Hulin Wu,et al.  A Bayesian approach for estimating antiviral efficacy in HIV dynamic models , 2006 .

[4]  Aki Vehtari.  Discussion to "Bayesian measures of model complexity and fit" by Spiegelhalter, D.J., Best, N.G., Carlin, B.P., and van der Linde, A. , 2002 .

[5]  H Wu,et al.  Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.

[6]  Adrian F. M. Smith,et al.  Sampling-Based Approaches to Calculating Marginal Densities , 1990 .

[7]  Marie Davidian,et al.  Nonlinear Models for Repeated Measurement Data , 1995 .

[8]  A A Ding,et al.  Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. , 1999, Mathematical biosciences.

[9]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[10]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Hulin Wu,et al.  Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. , 2004, The Journal of infectious diseases.

[12]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[13]  H Putter,et al.  A Bayesian approach to parameter estimation in HIV dynamical models , 2002, Statistics in medicine.

[14]  Davide Verotta,et al.  A Non-linear Mixed Effect Dynamic Model Incorporating Prior Exposure and Adherence to Treatment to Describe Long-term Therapy Outcome in HIV-patients , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[15]  Alan S. Perelson,et al.  Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  N. Shephard,et al.  Likelihood INference for Discretely Observed Non-linear Diffusions , 2001 .

[17]  L M Wahl,et al.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection , 1997, Journal of virology.

[18]  J. Wakefield.  The Bayesian Analysis of Population Pharmacokinetic Models , 1996 .

[19]  Davide Verotta,et al.  Models and estimation methods for clinical HIV-1 data , 2005 .

[20]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[21]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[22]  Hulin Wu,et al.  Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. , 2003, Mathematical biosciences.

[23]  A S Perelson,et al.  Rate of HIV‐1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen , 1998, AIDS.

[24]  L Zhu,et al.  Comparing hierarchical models for spatio-temporally misaligned data using the deviance information criterion. , 2000, Statistics in medicine.

[25]  Alan S. Perelson,et al.  Bayesian Analysis of a Population HIV Dynamic Model , 2002 .

[26]  L M Wahl,et al.  Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[28]  Hulin Wu,et al.  Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals , 2004, Journal of acquired immune deficiency syndromes.

[29]  Hermann Singer.  Parameter Estimation of Nonlinear Stochastic Differential Equations: Simulated Maximum Likelihood versus Extended Kalman Filter and Itô-Taylor Expansion , 2002 .

[30]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[31]  Hulin Wu,et al.  A Comparison Study of Models and Fitting Procedures for Biphasic Viral Dynamics in HIV‐1 Infected Patients Treated with Antiviral Therapies , 2000, Biometrics.

[32]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[33]  D Commenges,et al.  Maximum Likelihood Estimation in Dynamical Models of HIV , 2007, Biometrics.

[34]  A. Ding,et al.  Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. , 2001, Biostatistics.

[35]  Lang Wu,et al.  A Joint Model for Nonlinear Mixed-Effects Models With Censoring and Covariates Measured With Error, With Application to AIDS Studies , 2002 .

[36]  V De Gruttola,et al.  Estimation of HIV dynamic parameters. , 1998, Statistics in medicine.

[37]  J R Ickovics,et al.  Adherence in AIDS clinical trials: a framework for clinical research and clinical care. , 1997, Journal of clinical epidemiology.

[38]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[39]  S. E. Ahmed,et al.  Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference , 2008, Technometrics.